Live price temporarily unavailable.
ProKidney (PROK) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | $0 | $0 | $76.0K | $893.0K |
| Growth (year over year) | — | — | — | — | — | +1075.0% |
| Operating income | −$27.0M | −$55.1M | −$153.0M | −$151.5M | −$183.7M | −$165.0M |
| Operating margin | — | — | — | — | −241678.9% | −18477.8% |
| Net income | −$26.7M | −$55.1M | −$148.1M | −$35.5M | −$61.2M | −$69.0M |
| Net margin | — | — | — | — | −80507.9% | −7725.2% |
| EPS (diluted) | — | — | −$0.23 | — | — | — |
| Balance sheet | ||||||
| Cash and equivalents | $4.58M | $20.6M | $490.3M | $60.6M | $99.1M | $108.5M |
| Total assets | — | $40.3M | $518.0M | $420.6M | $441.1M | $335.6M |
| Total liabilities | — | $13.4M | $13.1M | $29.2M | $39.4M | $34.8M |
| Shareholders' equity | $9.86M | $26.9M | −$1.10B | −$1.10B | −$995.0M | −$1.01B |
| Cash flow | ||||||
| Operating cash flow | −$25.2M | −$50.3M | −$77.1M | −$90.1M | −$126.4M | −$120.1M |
| Capital expenditure | $5.46M | $5.19M | $1.85M | $34.2M | $29.5M | $15.2M |
| Free cash flow | −$30.6M | −$55.5M | −$78.9M | −$124.3M | −$155.9M | −$135.3M |
| Share buybacks | — | $0 | $0 | $9.50M | $0 | $0 |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $230.0K | $221.0K | $217.0K | $225.0K | $226.0K | $150.0K |
| Growth (year over year) | — | — | — | — | — | — | −1.7% | −32.1% |
| Operating income | −$49.0M | — | −$41.4M | −$39.7M | −$38.5M | −$45.4M | −$44.9M | −$48.4M |
| Operating margin | — | — | −17994.8% | −17967.9% | −17759.9% | −20164.9% | −19881.9% | −32248.7% |
| Net income | −$17.9M | — | −$16.7M | −$16.6M | −$16.5M | −$19.2M | −$20.0M | −$28.4M |
| Net margin | — | — | −7275.7% | −7489.6% | −7589.4% | −8547.1% | −8865.9% | −18948.0% |
| Balance sheet | ||||||||
| Cash and equivalents | $108.1M | $99.1M | $97.8M | $84.9M | $95.3M | $108.5M | $101.9M | $74.9M |
| Total assets | $474.8M | $441.1M | $406.1M | $372.1M | $351.6M | $335.6M | $292.8M | $249.0M |
| Total liabilities | $31.3M | $39.4M | $36.1M | $32.7M | $33.3M | $34.8M | $29.7M | $26.2M |
| Shareholders' equity | −$979.7M | −$995.0M | −$998.6M | −$1.00B | −$1.01B | −$1.01B | −$1.02B | −$883.5M |
| Cash flow | ||||||||
| Operating cash flow | −$29.2M | — | −$29.6M | −$31.4M | −$26.6M | −$32.5M | −$41.7M | −$40.4M |
| Capital expenditure | $2.40M | — | $1.14M | $3.11M | $5.20M | $5.75M | $3.79M | $3.83M |
| Free cash flow | −$31.6M | — | −$30.7M | −$34.5M | −$31.8M | −$38.3M | −$45.5M | −$44.2M |
From ProKidney's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning ProKidney in our feed yet.